Effect of Diisopropylamini Dichlorocacetas on Impairment of Hepatic Function in Patients with Sepsis_West China Medical Journal

Authors：

 ZENGLing-yong ,  HEZhi-bing

Department of Gastroenterology, People's Hospital of Neijiang Urban District, Neijiang, Sichuan 641000, P. R. China;

Corresponding author：

HEZhi-bing, Email: scnjzhzb@163.com

Keywords：

Diisopropylamini dichlorocacetas; Sepsis; Impairment of hepatic function

DOI：

10.7507/1002-0179.20150083

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the protective effects of diisopropylamini dichlorocacetas on impairment of hepatic function in patients with sepsis. Methods The 60 inpatients with liver dysfunction and sepsis treated in our hospital between June 2010 and December 2012 were randomly divided into two groups: treatment group (n=30) and control group (n=30). In the treatment group, patients were treated with intravenous diisopropylamini dichlorocacetas for 7 days, while patients in the control group were treated with Vitamin C for the same period. The venous blood sample of each patient of the two groups was collected and examined for the content of alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, alkaline phosphatase, total bilirubin, and direct bilirubin before and after treatment, and the effective rates of the two groups were determined. Results Liver function indicators after treatment of both the two groups were reduced. Compared with the control group, the liver function indicators were significantly decreased and the total effective rate was significantly higher in the treatment group (P<0.05). Conclusion Diisopropylamini dichlorocacetas is effective in the treatment of impairment of hepatic function in patients with sepsis.

Citation： ZENGLing-yong, HEZhi-bing. Effect of Diisopropylamini Dichlorocacetas on Impairment of Hepatic Function in Patients with Sepsis. West China Medical Journal, 2015, 30(2): 275-278. doi: 10.7507/1002-0179.20150083 Copy

1.	Camporota L, Wyncoll D. Practical aspects of treatment with drotrecogin alfa (activated)[J]. Crit Care, 2007, 11 (Suppl 5):7.
2.	Issa N, Messer J, Paganini EP. Renal assist device and treatment of sepsis-induced acute kidney injury in intensive care units[J]. Contrib Nephrol, 2007, 156(5):419-427.
3.	杨纯, 苏美仙. 脓毒血症患者免疫功能的改变与治疗对策[J]. 医学综述, 2010, 16(11):1604-1607.
4.	南川川, 孟祥林, 费东升, 等. 血红素氧合酶-1对老龄脓毒症大鼠微循环及肝脏功能的影响[J]. 中国老年学杂志, 2012, 32(7):1403-1406.
5.	秦溱, 高宏光, 刘鹏, 等. 高密度脂蛋白对严重脓毒症患者的预后相关分析[J]. 华西医学, 2013, 28(9):1345-1347.
6.	姚咏明, 盛志勇, 林洪远, 等. 脓毒症定义及诊断的新认识[J]. 中国危重症急救医学, 2004, 16(6):321-324.
7.	王今达, 王宝恩. 多脏器功能失常综合征(MODS) 病情分期诊断及严重程度评分标准[J]. 中国危重病急救医学, 1995, 7(6):346-347.
8.	Gordon AC, Lagan AL, Aganna E, et al. TNF and TNFR polymorphisms in severe sepsis and septic shock:a prospective multicentre study[J]. Genes Immun, 2004, 5(8):631-640.
9.	Bulger EM, May S, Kerby JD, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock:a randomized, placebo controlled trial[J]. Ann Surg, 2011, 253(3):431-441.
10.	Le BB. Pathology:a pictorial review. A selected atlas of paediatric liver pathology[J]. Clin Res Hepatol Gastroenterol, 2012, 36(3):248-252.
11.	Spahr L, Rubbia-Brandt L, Genevay M, et al. Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis[J]. BMC Gastroenterol, 2011, 11(1):115.
12.	Dell'Albani P, Santangelo R, Torrisi L, et al. JAK/STAT signaling pathway mediates cytokine induced iNOS expression in primary astroglial cell cultures[J]. J Neurosci Res, 2001, 65(5):417-424.
13.	王浩渊, 赵擎宇. 脓毒症肝损害机制和多烯磷脂酰胆碱的抗炎护肝作用研究进展[J]. 肝脏, 2007, 12(4):313-315.
14.	Kim TH, Lee SH, Lee SM. Role of Kupffer cells in pathogenesis of sepsis-induced drug metabolizing dysfunction[J]. FEBS J, 2011, 278(13):2307-2317.
15.	Jin SZ, Liu BR, Xu J, et al. Ex vivo-expanded bone marrow stem cells home to the liver and ameliorate functional recovery in a mouse model of acute hepatic injury[J]. Hepatobiliary Pancreat Dis Int, 2012, 11(1):66-73.
16.	Dupuis GS, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output[J]. JAMA, 2012, 307(9):948-955.
17.	韦丽娅, 翟永贞, 冯国和. 血清前白蛋白对肝功能评估的研究进展[J]. 世界华人消化杂志, 2013, 21(15):1387-1393.
18.	陆伦根, 曾民德, 茅益民, 等. 二氯醋酸二异丙胺治疗非酒精性脂肪性肝病的随机双盲临床研究[J]. 中华肝脏病杂志, 2005, 13(2):92-95.
19.	吴波. 复方二氯醋酸二异丙胺注射液治疗血脂异常87例[J]. 中国新药与临床杂志, 2010, 29(9):693-695.

1. Camporota L, Wyncoll D. Practical aspects of treatment with drotrecogin alfa (activated)[J]. Crit Care, 2007, 11 (Suppl 5):7.
2. Issa N, Messer J, Paganini EP. Renal assist device and treatment of sepsis-induced acute kidney injury in intensive care units[J]. Contrib Nephrol, 2007, 156(5):419-427.
3. 杨纯, 苏美仙. 脓毒血症患者免疫功能的改变与治疗对策[J]. 医学综述, 2010, 16(11):1604-1607.
4. 南川川, 孟祥林, 费东升, 等. 血红素氧合酶-1对老龄脓毒症大鼠微循环及肝脏功能的影响[J]. 中国老年学杂志, 2012, 32(7):1403-1406.
5. 秦溱, 高宏光, 刘鹏, 等. 高密度脂蛋白对严重脓毒症患者的预后相关分析[J]. 华西医学, 2013, 28(9):1345-1347.
6. 姚咏明, 盛志勇, 林洪远, 等. 脓毒症定义及诊断的新认识[J]. 中国危重症急救医学, 2004, 16(6):321-324.
7. 王今达, 王宝恩. 多脏器功能失常综合征(MODS) 病情分期诊断及严重程度评分标准[J]. 中国危重病急救医学, 1995, 7(6):346-347.
8. Gordon AC, Lagan AL, Aganna E, et al. TNF and TNFR polymorphisms in severe sepsis and septic shock:a prospective multicentre study[J]. Genes Immun, 2004, 5(8):631-640.
9. Bulger EM, May S, Kerby JD, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock:a randomized, placebo controlled trial[J]. Ann Surg, 2011, 253(3):431-441.
10. Le BB. Pathology:a pictorial review. A selected atlas of paediatric liver pathology[J]. Clin Res Hepatol Gastroenterol, 2012, 36(3):248-252.
11. Spahr L, Rubbia-Brandt L, Genevay M, et al. Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis[J]. BMC Gastroenterol, 2011, 11(1):115.
12. Dell'Albani P, Santangelo R, Torrisi L, et al. JAK/STAT signaling pathway mediates cytokine induced iNOS expression in primary astroglial cell cultures[J]. J Neurosci Res, 2001, 65(5):417-424.
13. 王浩渊, 赵擎宇. 脓毒症肝损害机制和多烯磷脂酰胆碱的抗炎护肝作用研究进展[J]. 肝脏, 2007, 12(4):313-315.
14. Kim TH, Lee SH, Lee SM. Role of Kupffer cells in pathogenesis of sepsis-induced drug metabolizing dysfunction[J]. FEBS J, 2011, 278(13):2307-2317.
15. Jin SZ, Liu BR, Xu J, et al. Ex vivo-expanded bone marrow stem cells home to the liver and ameliorate functional recovery in a mouse model of acute hepatic injury[J]. Hepatobiliary Pancreat Dis Int, 2012, 11(1):66-73.
16. Dupuis GS, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output[J]. JAMA, 2012, 307(9):948-955.
17. 韦丽娅, 翟永贞, 冯国和. 血清前白蛋白对肝功能评估的研究进展[J]. 世界华人消化杂志, 2013, 21(15):1387-1393.
18. 陆伦根, 曾民德, 茅益民, 等. 二氯醋酸二异丙胺治疗非酒精性脂肪性肝病的随机双盲临床研究[J]. 中华肝脏病杂志, 2005, 13(2):92-95.
19. 吴波. 复方二氯醋酸二异丙胺注射液治疗血脂异常87例[J]. 中国新药与临床杂志, 2010, 29(9):693-695.

West China Medical Journal

Effect of Diisopropylamini Dichlorocacetas on Impairment of Hepatic Function in Patients with Sepsis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content